The only potentially curative options for gastric cancer involve endoscopic or surgical resection, with adjunctive systemic ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Johnson & Johnson today announced new longer follow-up results from the investigational Phase 1b/2 OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor ...

In October 2025, Case Comprehensive Cancer Center announced a clinical trial is to see if shorter Photodynamic Therapy (PDT) ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...

Durvalumab plus FLOT chemotherapy significantly improved event-free survival and overall survival in gastric and gastroesophageal junction cancers. The MATTERHORN trial's perioperative approach ...

Introduction: The combination of liposomal irinotecan with fluorouracil and leucovorin (Nal-IRI/FL) has shown efficacy in phase II trials for advanced biliary tract cancer (BTC) following ...